One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB. In one embodiment, the composition includes a fibrate, such as gemfibrozil or fenofibrate. In another embodiment, the composition also includes all-trans retinoic acid or vitamin A.

One aspect of the invention provides a method for treatment of a lysosomal storage disorder. The method may include administering to a subject in need of such treatment a composition including a therapeutically effective amount of an agent that mediates upregulation of Transcription Factor EB. In one embodiment, the composition includes a fibrate, such as gemfibrozil or fenofibrate. In another embodiment, the composition also includes all-trans retinoic acid or vitamin A.

The present invention provides a novel cell penetrating peptide that transports proteins into cells and/or into nuclei and a pharmaceutical containing the peptide.

The present invention provides a novel cell penetrating peptide that transports proteins into cells and/or into nuclei and a pharmaceutical containing the peptide.

This disclosure provides a novel compositions and methods to deliver cyclosporine A using genetically engineered protein polymers.

The present invention provides a composition for relief or management of a pain associated with a disorder, e.g., joint or skeletal condition, the composition comprises n effective amount of retinoic acid. Methods of making and using the same are also disclosed.

The present invention provides a composition for relief or management of a pain associated with a disorder, e.g., joint or skeletal condition, the composition comprises n effective amount of retinoic acid. Methods of making and using the same are also disclosed.

The present invention provides a composition for relief or management of a pain associated with a disorder, e.g., joint or skeletal condition, the composition comprises n effective amount of retinoic acid. Methods of making and using the same are also disclosed.

Compositions and methods are for disclosed for treating a skin condition that results from reactive oxygen species production in skin of a subject, including applying a topical formulation that contains a lipophilic cation-mitochondrially targeted antioxidant compound and that delivers a therapeutically effective amount of the antioxidant compound to skin fibroblasts and keratinocytes.

Compositions and methods are for disclosed for treating a skin condition that results from reactive oxygen species production in skin of a subject, including applying a topical formulation that contains a lipophilic cation-mitochondrially targeted antioxidant compound and that delivers a therapeutically effective amount of the antioxidant compound to skin fibroblasts and keratinocytes.